21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer.

Chen XH1, Zhang WW2, Wang J3, Sun JY2, Li FY2, He ZY2, Wu SG3.

Author information

Abstract

AIM:

To determine the effect of the 21-gene recurrence score (RS) on outcome and chemotherapy decision in breast invasive lobular carcinoma (ILC).

MATERIALS & METHODS:

We included 6467 patients with early stage and estrogen receptor-positive ILC from the Surveillance, epidemiology, and end results database.

RESULTS:

A total of 9.1, 31.4, and 70.1% of patients with low-, intermediate-, and high-risk RS groups received chemotherapy, respectively. A higher RS was independently associated with poor breast cancer-specific survival, and receipt of chemotherapy was not related to better breast cancer-specific survival in low-, intermediate-, or high-risk RS groups.

CONCLUSION:

The 21-gene RS could impact chemotherapy decision making in early-stage ILC. However, adjuvant chemotherapy does not appear to improve outcome in high-risk RS cohort.